These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 11235048

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
    Atkinson HG.
    Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Current post-marketing information. Effects and adverse effects of celecoxib].
    Schmidt H, Geisslinger G.
    Pharm Unserer Zeit; 2002 Aug; 31(2):180-7. PubMed ID: 11977454
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA.
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [Abstract] [Full Text] [Related]

  • 33. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
    Kismet K, Akay MT, Abbasoglu O, Ercan A.
    Cancer Detect Prev; 2004 Nov; 28(2):127-42. PubMed ID: 15068837
    [Abstract] [Full Text] [Related]

  • 34. [COX-2 inhibitor to whom?].
    Martio J.
    Duodecim; 2000 Nov; 116(12):1265-7. PubMed ID: 11988961
    [No Abstract] [Full Text] [Related]

  • 35. The cost of COX inhibitors: how selective should we be?
    Marra CA, Esdaile JM, Sun H, Anis AH.
    J Rheumatol; 2000 Dec; 27(12):2731-3. PubMed ID: 11128654
    [No Abstract] [Full Text] [Related]

  • 36. Cox-2 inhibitors: a new class of medication?
    Habershaw TA.
    Med Health R I; 1999 Sep; 82(9):332-4. PubMed ID: 10517079
    [No Abstract] [Full Text] [Related]

  • 37. Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity.
    Mastalerz L, Sanak M, Gawlewicz-Mroczka A, Gielicz A, Cmiel A, Szczeklik A.
    Thorax; 2008 Jan; 63(1):27-34. PubMed ID: 17584993
    [Abstract] [Full Text] [Related]

  • 38. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
    Jüni P, Rutjes AW, Dieppe PA.
    BMJ; 2002 Jun 01; 324(7349):1287-8. PubMed ID: 12039807
    [No Abstract] [Full Text] [Related]

  • 39. [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects].
    Burdan F, Korobowicz A.
    Pol Merkur Lekarski; 2003 Apr 01; 14(82):352-5. PubMed ID: 12868201
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.